Kringle Pharma
4884.TPharmaceutical
Filed as Kringle Pharma, Inc. (2022-08–2026-05), Kringle Pharma, Inc (2023-05–2023-05)
Major holders (5%+) · 0
| Holder | Stake |
|---|
No holder currently reports 5% or more.
Each holder's own ratio from its most recent large-shareholding report.
Former and minor holders (below 5%) · 6
| Evo Fund | 4.79% |
| Barclays Bank PLC | 4.39% |
| TOHOKU University Venture Partners | 3.07% |
| Barclays Capital Securities Ltd. | 0.21% |
| Barclays Securities Japan Limited | 0.06% |
| Evolution Capital Management LLC | 0.00% |
Ownership history · 33
| Holder | Ratio | Change |
|---|---|---|
| Evolution Capital Management LLC2025-08-08 · amended | 0.00% | no change |
| Evo Fund2025-08-08 · amended | 20.32% | -1.18pp |
| Evolution Capital Management LLC2025-08-08 · amended | 0.00% | no change |
| Evo Fund2025-08-08 · amended | 21.50% | -0.98pp |
| Evolution Capital Management LLC2025-08-08 · amended | 0.00% | new |
| Evo Fund2025-08-08 · amended | 22.48% | new |
| TOHOKU University Venture Partners2024-07-05 · amended | 3.07% | new |
| Barclays Securities Japan Limited2024-02-19 · amended | 0.06% | +0.06pp |
| Barclays Capital Securities Ltd.2024-02-19 · amended | 0.21% | -0.27pp |
| Barclays Bank PLC2024-02-19 · amended | 4.39% | -1.22pp |
| Barclays Securities Japan Limited2024-01-29 · amended | 0.00% | new |
| Barclays Capital Securities Ltd.2024-01-29 · amended | 0.48% | new |
| Barclays Bank PLC2024-01-29 · amended | 5.61% | new |
Each holder in 5% reports, joint holders included. Purpose is classified from the filed text.